Navigation Links
Nfocus Neuromedical, Inc. Luna™ Aneurysm Embolization System Receives CE Mark
Date:2/15/2011

PALO ALTO, Calif., Feb. 15, 2011 /PRNewswire/ -- Nfocus Neuromedical, Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, announced today that its Luna™ Aneurysm Embolization System (AES) received CE Mark for the treatment of patients with brain aneurysms.  The Luna AES is designed to be a single-deployment, easy-to-use system for the treatment of brain aneurysms both pre- and post-rupture.  

"Brain aneurysm treatment historically has been the domain of either surgery or, more recently, catheter-placed wire coils," said Eric Milledge, CEO, Nfocus Neuromedical.  "Surgery can be traumatic and expensive, and coils may fail to fully treat an aneurysm.  The Luna AES represents a dramatic step forward in the treatment of these patients."

It is estimated that up to one in 15 people will develop a brain aneurysm during their lifetime.(1)  Rupture of an aneurysm can cause stroke, brain damage and even death.

The Luna AES treats brain aneurysms by blocking (embolizing) blood flow while providing a scaffold to encourage tissue growth across an aneurysm opening and create a plug. The Luna uses a self-expandable, multi-layer oval implant made from Nitinol, a nickel-titanium alloy. The properties of the device allow it to easily compress within a conventional catheter, and then rapidly and easily open to full size once deployed within an aneurysm.

"CE Mark approval is an important milestone for Nfocus," said Robert O'Holla, vice president of regulatory affairs, Nfocus Neuromedical.  "The Luna AES is our flagship product and we look forward to working with physicians and hospitals in Europe to advance this important new technology."

About Nfocus Neuromedical, Inc.

Nfocus is developing the next generation treatment for brain aneurysms. The company's innovative LUNA™ product is a single-deployment, easy-to-use embolization device designed to be a direct replacement to detachable coils. Nfocus is backed by three major U.S.- and OUS-based venture funds: DFJ ePlanet Capital, Technology Partners, and InCube Ventures. Other investors include Raffles Capital and Endeavor Vision. More information can be found at www.nfocusneuro.com.

(1) - http://www.brainaneurysm.com/


'/>"/>
SOURCE Nfocus Neuromedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nfocus Neuromedical Announces FDA 510(k) Clearance for Next Generation Device to Treat Vascular Lesions
2. Verathon(R) Helps Physicians Identify the Presence of Abdominal Aortic Aneurysms with New AortaScan(TM) Brand of Portable Ultrasound Aortic Measurement Instruments
3. Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment
4. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
5. Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms
6. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
7. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
8. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
9. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
10. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
11. Endovascular Forum and GEST Set Out on a Shared Venture to Bring the Highest Level of Embolization-based Scientific and Technical Education, Results, and Relevance for Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... communities in the greater Dallas, Miami, and Raleigh regions, is organizing an extended ... overcome a rare and deadly chromosome abnormality. , After struggling since birth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):